Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy

Pediatrics International

Volumn 44, Issue 3, 2002, Pages 247-253

  Tsukahara, Hirokazu ^a   Kimura, Kouki ^a   Todoroki, Yukiko ^a   Ohshima, Yusei ^a   Hiraoka, Masahiro ^a   Shigematsu, Yosuke ^a   Tsukahara, Yasuyo ^a   Miura, Masakazu ^b   Mayumi, Mitsufumi ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b LSI MEDIENCE CORPORATION   (Japan)

Author keywords

Bone markers; Bone metabolism; Calcium intake; Dual energy X ray absorptiometry; Long term anti epileptic treatment

Indexed keywords

CALCITRIOL; CARBAMAZEPINE; CLONAZEPAM; ETHOSUXIMIDE; OSTEOCALCIN; PARATHYROID HORMONE; PHENOBARBITAL; PROCOLLAGEN C PROTEINASE; PYRIDINOLINE; VALPROIC ACID;

ADOLESCENT; ANTICONVULSANT THERAPY; ARTICLE; BONE CELL; BONE DENSITY; BONE MINERAL; BONE MINERALIZATION; BONE TURNOVER; CALCIUM INTAKE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; EPILEPSY; FEMALE; GENOTYPE; HUMAN; LUMBAR SPINE; MALE; OSTEOPENIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SEX DIFFERENCE;

ADOLESCENT; ANTICONVULSANTS; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES, METABOLIC; CALCIUM, DIETARY; CARBAMAZEPINE; CHILD; DENSITOMETRY, X-RAY; EPILEPSY; FEMALE; HUMANS; LUMBAR VERTEBRAE; MALE; RECEPTORS, CALCITRIOL; SEX FACTORS; VALPROIC ACID;

EID: 0036316126     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-200X.2002.01561.x     Document Type: Article

References (28)

1. Physiologic and metabolic aspects of anticonvulsants
2. Strategies to protect bone mass in the older patient with epilepsy
3. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment
4. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs
5. Analysis of urinary pyridinoline and deoxypyridinoline in patients undergoing long-term antivonvulsant drug therapy
6. Increased bone turnover in epileptic patients treated with carbamazepine
7. Changes in bone turnover and deoxypyridinoline levels in epileptic patients
8. Long-term anticonvulsant therapy leads to low bone mineral density: Evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells
9. Bone status of children receiving anticonvulsant therapy
10. Decreased bone density in severely handicapped children and adults, with reference to the influence of limited mobility and anticonvulsant medication
11. Long-term anticonvulsant therapy and vitamin D metabolism in ambulatory pubertal children
12. Effects of anticonvulsant drug therapy on bone mineral density in a pediatric population
13. Increased circulating levels of γ-carboxyglutamic acid-containing protein and decreased bone mass in children on anticonvulsant therapy
14. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children
15. Effect of carbamazepine and valproate on bone mineral density
16. Evaluation of bone mineral density in children receiving antiepileptic drugs
17. Valproate therapy: Predisposition to bone fracture?
18. Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years
19. Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid
20. Evaluation of lumbar bone mineral density by dual energy x-ray absorptiometry
21. Bone mineral density of the lumbar spine and total body mass in Japanese children and adolescents
22. Measurement of serum osteocalcin (bone gla protein) and procollagen-III-peptide as growth factors in children
23. Serum levels of carboxyterminal propeptide of type I procollagen and pyridinoline crosslinked telopeptide of type I collagen in normal children and children with growth hormone (GH) deficiency during GH therapy
24. Vitamin D receptor alleles, bone mineral density and turnover in premenopausal Japanese women
25. What does bone work? How do we strengthen it?
26. Involutional osteoporosis
27. Phenytoin affects osteocalcin secretion from osteoblastic rat osteosarcoma 17/2.8 cells in culture
28. Calcium supplementation and increases in bone mineral density in children